Evidence map›Paper›PMID 27226240›Full record

ArticleScientific reports2016

Efficient antitumor effect of co-drug-loaded nanoparticles with gelatin hydrogel by local implantation.

Hao Zhang, Yong Tian, Zhenshu Zhu, Huae Xu, Xiaolin Li, Donghui Zheng, Weihao Sun

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Hao ZhangDepartment of Geriatrics, the First Affiliated Hospital to Nanjing Medical University, Nanjing, 210029, China.
Yong TianDepartment of Orthopaedics, Jiangsu Taizhou People's Hospital, Taizhou, 225300, China.
Zhenshu ZhuKey Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing 210009, China.
Huae XuDepartment of Pharmacy, the First Affiliated Hospital to Nanjing Medical University, Nanjing, 210029, China.
Xiaolin LiDepartment of Geriatrics, the First Affiliated Hospital to Nanjing Medical University, Nanjing, 210029, China.
Donghui ZhengDepartment of Nephrology, Huai'an Hospital Affiliated with Xuzhou Medical College and Huai'an Second Hospital, Huai'an 223002, China.
Weihao SunDepartment of Geriatrics, the First Affiliated Hospital to Nanjing Medical University, Nanjing, 210029, China.
Nanjing Medical University · CNChina Pharmaceutical University · CNSecond People’s Hospital of Huai’an · CNTaizhou People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetrandrine (Tet) could enhance the antitumor effect of Paclitaxel (Ptx) by increasing intracellular Reactive Oxygen Species (ROS) levels, which leads to the possibility of co-delivery of both drugs for synergistic antitumor effect. In the current study, we reported an efficient, local therapeutic strategy employing effective Tet and Ptx delivery with a nanoparticle-loaded gelatin system. Tet- and Ptx co-loaded mPEG-PCL nanoparticles (P/T-NPs) were encapsulated into the physically cross-linked gelatin hydrogel and then implanted on the tumor site for continuous drug release. The drug-loaded gelatin hydrogel underwent a phase change when the temperature slowly increased. In vitro study showed that Tet/Ptx-loaded PEG-b-PCL nanoparticles encapsulated within a gelatin hydrogel (P/T-NPs-Gelatin) inhibited the growth and invasive ability of BGC-823 cells more effectively than the combination of free drugs or P/T-NPs. In vivo study validated the therapeutic potential of P/T-NPs-Gelatin. P/T-NPs-Gelatin significantly inhibited the activation of p-Akt and the downstream anti-apoptotic Bcl-2 protein and also inducing the activation of pro-apoptotic Bax protein. Moreover, the molecular-modulating effect of P/T-NPs-Gelatin on related proteins varied slightly under the influence of NAC, which was supported by the observations of the tumor volumes and weights. Based on these findings, local implantation of P/T-NPs-Gelatin may be a promising therapeutic strategy for the treatment of gastric cancer.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBenzylisoquinolinesCell Line, TumorCell MovementCell ProliferationDelayed-Action PreparationsDrug CarriersDrug SynergismGelatinGene Expression Regulation, NeoplasticHumansHydrogelsMiceNanoparticlesAntineoplastic Agents, PhytogenicBCL2 protein, humanBenzylisoquinolinesDelayed-Action PreparationsDrug CarriersGelatinHydrogelsPaclitaxelProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2tetrandrine

Identifiers

PMID27226240
PMCPMC4880919
OpenAlexW2408471207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.